Glory: Entrepreneurs in the 1990s

Raising capital is tougher than ever, but analysts voice optimism for scientist-business people with viable products In mid-1989, George Rathmann decided to leave his post as chairman of Amgen Inc. of Thousand Oaks, Calif., a biotechnology company he cofounded in 1980, to embark on another biotech venture. He joined Bob Nowinski (founder of Genetic Systems Corp. in Seattle) and Chris Henney (founder of Immunex Corp. also of Seattle) to form ICOS Corp., which was incorporated in late 1989. The

Written bySusan L-J Dickinson
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Would-be entrepreneurs may not believe such a smooth startup scenario, and even Rathmann sounds a little stunned at the Proof that "a strategy that did everything concurrently worked." To be sure, few first-time scientist entrepreneurs could have pulled off such a coup. But at a time when headlines emphasize impending economic despair -- bank closings, layoffs, and business failures-- the ICOS story does offer hope to science entrepreneurs that the coming decade, recession or no recession, will be a fruitful one.

"On the leading edge of technology there is always opportunity for new ventures, new companies, and newcomers," says Rathmann (see interview, page 13). Indeed, pundits prophesy that the 1990s will be a decade of change and opportunity in the world of high-tech startups. New scientific fields will be ready for commercialization, new funding sources will, of necessity, come to light, and new geographic foci -- fertile alternatives to the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies